ArticleJournal of global infectious diseases
Post-COVID-19 Condition has High Prevalence in Patients with Immune-mediated Inflammatory Diseases and Negatively Impacts Quality of Life.
Article in Journal of global infectious diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pandemic situation by severe acute respiratory syndrome coronavirus 2 and the associated disease (coronavirus disease 2019 [COVID-19]) presents broad challenges. Post-COVID-19 condition represents a continuum of persistent symptoms following the acute course. The World Health Organization (WHO) proposes a definition with at least one symptom persisting for 3 months postonset. Negative affection toward quality of life (QoL) is frequently reported. Patients with immune-mediated inflammatory diseases (IMIDs), such as inflammatory bowel disease (IBD) and rheumatic diseases (RDs) are of scientific interest as immunologic factors and immunosuppressive therapy might influence QoL in post-COVID-19 conditions. Methods: Adult IMID patients (≥18 years) were offered participation in this study at our university outpatient center. Data collection was questionnaire-based and recorded individual COVID-19 history and persisting symptoms. QoL has been assessed by several standardized and validated patient-reported outcome measures (Short IBD Questionnaire and Patient Health Questionnaire 4, 5Q-5D-5L). Results: A total of 156 patients were included (117 [75%] with IBD, 39 [25%] with RDs). Eighty-one patients (51%) reported a positive COVID-19 history, mostly with mild courses. Only two (2%) required hospitalization, one requiring intensive care. Seven (9%) reported no symptoms, while 20 (25%) met the WHO criterion for post-COVID-19 condition; 19 (23%) were still suffering from post-COVID-19 at the time of data acquisition. Mean/median global QoL scores (scale from 0 [=lowest] to 100 [=highest]) were 71.5/75 in patients without post-COVID-19, compared to 61.9/60 in those with the condition. A one-sided Conclusions: A relevant fraction of IMID patients suffered from post-COVID-19 condition. This condition negatively impacted the individual QoL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.